These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24469045)

  • 1. PRC2-independent chromatin compaction and transcriptional repression in cancer.
    Vallot C; Hérault A; Boyle S; Bickmore WA; Radvanyi F
    Oncogene; 2015 Feb; 34(6):741-51. PubMed ID: 24469045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.
    Coward WR; Feghali-Bostwick CA; Jenkins G; Knox AJ; Pang L
    FASEB J; 2014 Jul; 28(7):3183-96. PubMed ID: 24652950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
    Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
    Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains.
    Donaldson-Collier MC; Sungalee S; Zufferey M; Tavernari D; Katanayeva N; Battistello E; Mina M; Douglass KM; Rey T; Raynaud F; Manley S; Ciriello G; Oricchio E
    Nat Genet; 2019 Mar; 51(3):517-528. PubMed ID: 30692681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.
    Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J
    Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycomb-mediated genome architecture enables long-range spreading of H3K27 methylation.
    Kraft K; Yost KE; Murphy SE; Magg A; Long Y; Corces MR; Granja JM; Wittler L; Mundlos S; Cech TR; Boettiger AN; Chang HY
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2201883119. PubMed ID: 35617427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for transmission of the H3K27me3 epigenetic mark.
    Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
    Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.
    Chinaranagari S; Sharma P; Chaudhary J
    Oncotarget; 2014 Aug; 5(16):7172-82. PubMed ID: 25115397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
    Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
    Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
    [No Abstract]   [Full Text] [Related]  

  • 11. IMITATION SWITCH is required for normal chromatin structure and gene repression in PRC2 target domains.
    Kamei M; Ameri AJ; Ferraro AR; Bar-Peled Y; Zhao F; Ethridge CL; Lail K; Amirebrahimi M; Lipzen A; Ng V; Grigoriev IV; Schmitz RJ; Liu Y; Lewis ZA
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
    Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
    PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.
    Ma X; Wang J; Wang J; Ma CX; Gao X; Patriub V; Sklar JL
    Oncotarget; 2017 Jan; 8(3):4062-4078. PubMed ID: 27845897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
    Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
    Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
    Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
    Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
    Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
    Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.